NO for preterm infants at risk of bronchopulmonary dysplasia

Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
The Lancet (Impact Factor: 45.22). 07/2010; 376(9738):308-10. DOI: 10.1016/S0140-6736(10)61051-3
Source: PubMed
1 Follower
3 Reads
  • American Journal of Respiratory and Critical Care Medicine 06/2011; 183(11):1477-81. DOI:10.1164/rccm.201102-0310UP · 13.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: When asked to address the above question, findings that appeared to be among the most relevant included (1) interventions in the delivery room directed at supporting the physiological transition from intrauterine to extrauterine life rather than actively intervening in it; (2) recent data suggesting that keeping extremely low-gestational age neonates at a pulse oximeter saturation (SpO(2)) of 91-95% would increase their chances of survival compared with aiming for lower SpO(2) values; (3) using caffeine citrate in infants <1250 g with apnoea of prematurity improves neurodevelopmental outcome; (4) injecting antivascular epithelial growth factor into the vitreous seems to be an effective treatment for retinopathy of prematurity and (5) moderate hypothermia for perinatal hypoxic-ischaemic encephalopathy increases the likelihood of survival without neurological impairment. Here, data that support these recent changes in approach will be presented and discussed.
    Archives of Disease in Childhood - Fetal and Neonatal Edition 08/2011; 98(1). DOI:10.1136/archdischild-2011-300641 · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the past, there has been a perception that ethical and practical problems limit the opportunities for research in neonates. This perception is no longer appropriate. It is now clear that research about the medicines used in neonates is an ethical requirement. It is possible to conduct high quality research in neonates if the research team adapt to the characteristics of this population. Good practice involves respecting the specific needs of newborn babies and their families by adopting relevant approaches to study design, recruitment, pharmacokinetic studies and safety assessment. Neonatal units have a unique culture that requires careful development in a research setting. Clinical investigators need to recognise the clinical and ethical imperative to conduct rigorous research. Industry needs to engage with neonatal networks early in the process of drug development, preferably before contacting regulatory agencies. Follow-up over 3 – 5 years is essential for the evaluation of medicines in neonates and explicit funding for this is required for the assessment of the benefit and risk of treatments given to sick newborn babies. The views of parents must be central to the development of studies and the research agenda. Ethical and practical problems are no longer barriers to research in neonates. The current challenges are to disseminate good practice and maximise capacity in order to meet the need for research among newborn babies.
    British Journal of Clinical Pharmacology 07/2014; 79(3). DOI:10.1111/bcp.12467 · 3.88 Impact Factor